Nephrology Medical News about Mycophenolate

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Enteric Coating of Mycophenolate Reduces Dosage Adjustments
Transplantation Proceedings, 07/02/09

Brister K et al. - Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) are bioequivalent. However, the effectiveness of MMF may be limited by gastrointestinal (GI) side effects. Patients receiving MMF required more immunosuppressive medication adjustments, which may complicate care and decrease overall compliance.

<< Previous
Kidney Graft Function in Long-term Cyclosporine and Tacrolimus...

Next >>
Epidural Infusion of Bupivacaine with Morphine for Pain Relief...

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09 Relevance Score: 85%

A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids
Liver Transplantation, 11/03/09 Relevance Score: 84%

Severe acute fibrinous and organizing pneumonia (AFOP) causing ventilatory failure: Successful treatment with mycophenolate mofetil and corticosteroids
Respiratory Medicine, 10/14/09 Relevance Score: 84%

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Kidney International, 11/05/09 Relevance Score: 83%

Safety and Tolerance of Sodium Mycophenolate in Patients After Renal Transplantation--An Observational Study
Transplantation Proceedings, 11/05/09 Relevance Score: 83%